Since the COVID-19 vaccines were authorized, global leaders aimed to innoculate as much of the population as they could. Tempting as it may sound, herd immunity turned out to be a distant and hard to achieve goal. Though children tend to be rather asymptomatic than suffer from severe COVID-19 symptoms, there are many of them actually dying of MIS-C.
Of course, it wasn’t an easy decision to make and Pfizer proved its top results since March. After all, it turns out efficacy among adolescents aged 12-15 is better than those of 16-25. The Director of FDA’s Center for Biologics Evaluation and Research claims Pfizer COVID-19 vaccine is 100 % effective and shows a great immune response. In an evening briefing, FDA Acting Commissioner Dr. Janet Woodcock assured:
CDC Advisory Committee on Immunization Practice meets on Wednesday, but it’s up to every state licensing board to make decisions. Canada already gave a green light to using Pfizer COVID-19 vaccine for children aged 12-15 last week. When including them in calculations, adding 5 % to the count, which gives a total of 85 % of the population. Actually, study on Pfizer COVID-19 vaccine safety and efficacy in children ages 6 months to 11 years old is ongoing. In September the company expects to gain authorization for emergency use for children ages 2 to 11 years. As for children under 12, the FDA Vaccines and Related Biological Products Advisory Committee is gathering on June 10.
More detailed, 2,260 adolescents participated in the Pfizer COVID-19 vaccine trial, and 18 of them received a placebo effect. Although it didn’t mean to prevent COVID-19 disease, but trigger an immune response, the vaccine actually offered robust protection. However, Pfizer will be monitoring for long-term protection and safety for an additional two years after their second dose.
So, we can easily say the future of the COVID-19 pandemic lies all in our hands. For the government, it’s clear to innoculate more Americans , and make it in the safest and quickest means. However, that doesn’t stop anti-vaxxers from suspicions and conspiracy theories, neither worries people normally express when trying something new. Including children in COVID-19 battle is in order to keep them protected, as they’re already involved in the pandemic, anyways.
MVS Pharma GmbH is an innovative pharmaceutical start-up company, which researches in the area of reducing viruses and bacteria with plant based aerosols. Their special formula ensures the purity and the stability of the used ingredients during storage.
Liliya Ganeva is an article writer, who explores all the actual, up-to-date COVID-19 information, and the possibilities for producing aerosols made out of plants against respiratory viruses and bacteria.